Mukherjee, Sudipto http://orcid.org/0000-0002-8325-2603
Kanhai, Karan
Kauffman, David
Martin, Rabecka
Paige, Jeremy S.
Ghosh, Anirvan
Kannan, Hannah
Shupo, Francis
Fajgenbaum, David C. http://orcid.org/0000-0002-7367-8184
Article History
Received: 3 June 2022
Revised: 15 August 2022
Accepted: 18 August 2022
First Online: 29 September 2022
Change Date: 16 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-022-01791-y
Competing interests
: The author(s) received no financial support for the research, authorship, and/or publication of this manuscript. DCF has received research funding from EUSA Pharma, received consulting fees from EUSA Pharma, and has a provisional patent pending related to JAK1/2 inhibition in iMCD and predictive biomarkers in iMCD. JSP is a paid consultant for Eversana, Inc. DK, AG, and HK are employees of Eversana, Inc. KK, RM, and FS are employees of EUSA Pharma. SM has received research funding from BMS, Novartis and Jazz Pharmaceuticals; honorarium from EUSA Pharma, Novartis, Celgene/Acceleron, BMS, Blueprint Medicines, Genentech and AbbVie, Aplastic Anemia and MDS International Foundation, EUSA, and Partnership for Health Analytic Research, LLC (PHAR, LLC).